Amniotic fluid embolism rare but associated with maternal mortality: JAMA

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-11-21 14:30 GMT   |   Update On 2022-11-21 14:30 GMT
Advertisement

Los Angeles: Findings from a national-level analysis published in JAMA Network Open have confirmed the dismal outcomes of pregnancies complicated by an amniotic fluid embolism (AFE) and indicate the placental accreta spectrum (PAS) may be associated with AFE.

Amniotic fluid embolism is a rare pregnancy complication which leads to higher maternal mortality. Because of the uncommonness of AFE, associated risk factors and maternal outcomes have not been studied well. Considering this, in a retrospective cohort study, Genevieve R. Mazza, University of Southern California, Los Angeles, and colleagues aimed to investigate the pregnancy, clinical, and delivery characteristics and the maternal outcomes tied to AFE.

The study examined hospital deliveries from the National Inpatient Sample of the Healthcare Cost and Utilization Project between January 1, 2016, to December 31, 2019. Pregnancy, clinical, and delivery characteristics of amniotic fluid embolism were assessed with a multivariable binary logistic regression model (primary outcome). The researchers also evaluated the associations with other indicators of severe maternal morbidity and failure to rescue per clinical and pregnancy characteristics. Failure to rescue was defined as maternal mortality after AFE (coprimary outcome).

The authors reported the following findings:

  • Out of a total 14 684 135 deliveries examined, AFE was diagnosed in 880 women, reflecting an incidence rate of 6.0 for each 100 000 deliveries. The median patient age was 29 years.
  • In a multivariable analysis, (1) patient factors of Asian and Black race, older age, pregestational hypertension, grand multiparity, illicit substance use, Western US region, and asthma; (2) pregnancy factors of PAS, uterine rupture, placental abruption, polyhydramnios, chorioamnionitis, preeclampsia, fetal demise and fetal growth restriction; and (3) delivery factors of early gestational age, cesarean delivery, cervical ripening, operative delivery, and manual removal were linked with AFE. Among these characteristics, PAS had the most significant association with AFE.
  • More severe PAS forms had a more significant association with AFE (aOR for increta and percreta, 17.35 and aOR for accreta, 7.62).
  • Patients having AFE were more likely to have a cardiac arrest, coagulopathy, and adult respiratory distress syndrome.
  • Overall, the failure-to-rescue rate after AFE was 17.0%. However, in cases where AFE co-occurred with other indicators of severe maternal morbidity, the failure-to-rescue rate exceeded 30%: 45.8% for AFE, cardiac arrest, and coagulopathy; 43.2% for AFE, shock, and cardiac rhythm conversion; and 38.6% for AFE, cardiac arrest, coagulopathy, and shock.
  • In the setting of placental pathology, when AFE occurred, the failure-to-rescue rate after AFE also exceeded 30%: 31.3% for AFE and placental abruption and 42.9% for AFE and PAS.

"The study confirmed that AFE is a rare complication of pregnancy but is linked with the significant maternal outcome," the researchers wrote. "Further studies are required to address the association between placental accreta spectrum and amniotic fluid embolism."

The researchers also stress the importance of establishing and distributing the universal diagnostic criteria for AFE.

Reference:

Mazza GR, Youssefzadeh AC, Klar M, et al. Association of Pregnancy Characteristics and Maternal Mortality With Amniotic Fluid Embolism. JAMA Netw Open. 2022;5(11):e2242842. doi:10.1001/jamanetworkopen.2022.42842


Tags:    
Article Source : JAMA Network Open

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News